Talk:Reata Pharmaceuticals

It is herein proposed that the topic of limiting the study to Type 2 Diabetes be explained and discussed. Additions from anyone having direct knowledge of this facet of the study involving the effects of bardoxolone methyl on renal disease would be appreciated. It would also be interesting to know if any other country is currently prescribing it for use in the treatment of real disease, and, if so, what their results have been.FriendMR (talk) 02:45, 7 October 2011 (UTC)